BRPI0512569A - métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano - Google Patents
métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humanoInfo
- Publication number
- BRPI0512569A BRPI0512569A BRPI0512569-3A BRPI0512569A BRPI0512569A BR PI0512569 A BRPI0512569 A BR PI0512569A BR PI0512569 A BRPI0512569 A BR PI0512569A BR PI0512569 A BRPI0512569 A BR PI0512569A
- Authority
- BR
- Brazil
- Prior art keywords
- eye
- mammal
- reduce
- formation
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58229304P | 2004-06-23 | 2004-06-23 | |
US62969504P | 2004-11-19 | 2004-11-19 | |
US66090405P | 2005-03-11 | 2005-03-11 | |
US67240505P | 2005-04-18 | 2005-04-18 | |
PCT/US2005/020080 WO2006007314A1 (en) | 2004-06-23 | 2005-06-06 | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0512569A true BRPI0512569A (pt) | 2008-03-25 |
Family
ID=34981643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0512569-3A BRPI0512569A (pt) | 2004-06-23 | 2005-06-06 | métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano |
Country Status (27)
Country | Link |
---|---|
US (3) | US8314152B2 (pt) |
EP (3) | EP1768657B1 (pt) |
JP (1) | JP4855396B2 (pt) |
KR (1) | KR100862930B1 (pt) |
AR (1) | AR049929A1 (pt) |
AT (1) | ATE404188T1 (pt) |
AU (1) | AU2005262558B8 (pt) |
BR (1) | BRPI0512569A (pt) |
CA (1) | CA2569691C (pt) |
CY (1) | CY1110435T1 (pt) |
DE (1) | DE602005008970D1 (pt) |
DK (1) | DK1768657T3 (pt) |
EA (1) | EA011864B1 (pt) |
ES (1) | ES2313368T3 (pt) |
GE (1) | GEP20084520B (pt) |
HK (1) | HK1107671A1 (pt) |
IL (1) | IL179872A (pt) |
LV (1) | LV13564B (pt) |
MX (1) | MXPA06014978A (pt) |
NO (1) | NO20070408L (pt) |
NZ (1) | NZ551955A (pt) |
PL (1) | PL1768657T3 (pt) |
PT (1) | PT1768657E (pt) |
SG (1) | SG140607A1 (pt) |
SI (1) | SI1768657T1 (pt) |
TW (1) | TWI396532B (pt) |
WO (1) | WO2006007314A1 (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2327400A3 (en) | 2003-03-14 | 2011-10-19 | University of Washington | Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof |
JP2007525496A (ja) * | 2004-02-17 | 2007-09-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 黄班変性症を含む眼科疾患の管理 |
US7566808B2 (en) | 2004-02-17 | 2009-07-28 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
KR20060135819A (ko) | 2004-02-17 | 2006-12-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 황반변성을 포함하는 안과질환의 관리 |
BRPI0511396B1 (pt) | 2004-06-18 | 2021-07-27 | University Of Washington | Uso de 9-cis-retinil éster e uso de um derivado de retinal sintético |
EP1768657B1 (en) | 2004-06-23 | 2008-08-13 | Sirion Therapeutics, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivates |
US20060089411A1 (en) * | 2004-08-07 | 2006-04-27 | Gierhart Dennis L | Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin |
EP1778207A2 (en) * | 2004-08-18 | 2007-05-02 | Sytera Inc. | Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
CN101048139A (zh) * | 2004-10-28 | 2007-10-03 | 艾德克斯实验室公司 | 药物活性化合物的控释组合物 |
KR20070091283A (ko) * | 2004-11-04 | 2007-09-10 | 시리온 테라퓨틱스, 인크. | 레티놀-레티놀 결합단백질(rbp)-트랜스타이레틴(ttr) 복합체 형성의조절 인자 |
EP2289500A1 (en) * | 2004-12-08 | 2011-03-02 | ReVision Therapeutics, Inc. | Retinol binding protein and transthyretin modulators for treating hypertosis, Alzheimer's disease or idiopathic intracranial hypertension |
UA81382C2 (en) * | 2005-07-11 | 2007-12-25 | Composition for treating retinol-related diseases by modulation of retinol binding | |
US7754679B2 (en) * | 2005-11-16 | 2010-07-13 | Idexx Laboratories, Inc. | Pharmaceutical compositions for the administration of aptamers |
US8114440B2 (en) * | 2005-11-16 | 2012-02-14 | Idexx Laboratories Inc. | Pharmaceutical compositions for the administration of aptamers |
WO2007150046A2 (en) * | 2006-06-22 | 2007-12-27 | Sirion Therapeutics, Inc | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity |
WO2008013983A2 (en) * | 2006-07-27 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Opsin stabilizing compounds and methods of use |
WO2008013984A2 (en) * | 2006-07-27 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Compositions and methods for treating or preventing ophthalmic disease |
CA2657164A1 (en) * | 2006-07-27 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Compositions and methods for treating or preventing ophthalmic light toxicity |
US8828960B2 (en) * | 2007-07-17 | 2014-09-09 | Idexx Laboratories, Inc. | Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds |
WO2009102418A1 (en) * | 2008-02-11 | 2009-08-20 | University Of Washington | Methods for the treatment and prevention of age-related retinal dysfunction |
WO2009114136A2 (en) * | 2008-03-12 | 2009-09-17 | Albert Einstein College Of Medicine Of Yeshiva University | Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents |
CN102099013A (zh) * | 2008-07-14 | 2011-06-15 | 奥德纳米有限公司 | 用于治疗耳部病症的控制释放凋亡调节组合物和方法 |
US20120108665A1 (en) * | 2009-05-04 | 2012-05-03 | Revision Therapeutics, Inc. | Methods and compositions for treating ophthalmic conditions |
IN2012DN00352A (pt) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
KR101710505B1 (ko) | 2009-09-15 | 2017-02-27 | 노벨리언 테라퓨틱스 인코포레이티드 | 리피드 비히클에 9-시스-레티닐 에스테르를 포함하는 약제 처방 |
JP5815552B2 (ja) | 2009-12-08 | 2015-11-17 | ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University | 眼疾患を治療する化合物および方法 |
RU2622763C2 (ru) | 2010-04-19 | 2017-06-19 | Новелион Терапьютикс Инк. | Лечебная схема и способы лечения или уменьшения нарушений зрения, связанных с дефицитом эндогенных ретиноидов |
CA2862807A1 (en) | 2011-11-30 | 2013-06-06 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
EP2797601B1 (en) * | 2012-02-10 | 2018-03-21 | Taiwan Liposome Company Ltd | Pharmaceutical compositions to reduce complications of ocular steroid |
BR112014021602A2 (pt) | 2012-03-01 | 2021-06-08 | Quadra Logic Tech Inc | uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide |
WO2014003850A2 (en) | 2012-06-26 | 2014-01-03 | Timothy Paul Foster | Methods for treatment of ocular diseases |
US9011845B2 (en) | 2012-06-26 | 2015-04-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods for treatment of inflammatory and infectious viral diseases |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
US10092393B2 (en) | 2013-03-14 | 2018-10-09 | Allotex, Inc. | Corneal implant systems and methods |
US10471118B2 (en) * | 2014-05-30 | 2019-11-12 | Case Western Reserve University | Retinylamine derivitives for treatment of ocular disorders |
EP3848353A1 (en) | 2014-10-24 | 2021-07-14 | Takeda Pharmaceutical Company Limited | Medicaments for the treatment of ophthalmic diseases |
JP2017538728A (ja) * | 2014-12-19 | 2017-12-28 | ケミン、インダストリーズ、インコーポレーテッドKemin Industries, Inc. | イオントフォレシスを用いた生物活性分子の眼内送達 |
US10449090B2 (en) | 2015-07-31 | 2019-10-22 | Allotex, Inc. | Corneal implant systems and methods |
EP3416622B1 (en) * | 2016-02-15 | 2023-06-28 | Kemin Industries, Inc. | Positively charged liposomes as lipophilic molecule carriers |
US11395853B2 (en) * | 2016-06-23 | 2022-07-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions |
KR20190090844A (ko) | 2016-12-05 | 2019-08-02 | 더 잭슨 래보라토리 | 인간에서의 신경퇴화 및 녹내장에 대한 진단적 마커로서의 망막 및 시신경 내 지방 알갱이 |
TW201906635A (zh) | 2017-07-04 | 2019-02-16 | 日商第一三共股份有限公司 | 伴隨視細胞變性的視網膜變性的疾病用藥 |
MX2021013609A (es) * | 2019-05-06 | 2022-04-06 | Univ California | Materiales y métodos para tratar la degeneración macular relacionada con la edad. |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4190594A (en) | 1975-11-03 | 1980-02-26 | Johnson & Johnson | Retinoic acid derivatives |
US4323581A (en) | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
US4665098A (en) | 1985-03-28 | 1987-05-12 | Mcneilab, Inc. | Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability |
US4874795A (en) | 1985-04-02 | 1989-10-17 | Yesair David W | Composition for delivery of orally administered drugs and other substances |
US4673044A (en) * | 1985-08-02 | 1987-06-16 | Eastman Christensen Co. | Earth boring bit for soft to hard formations |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4682663A (en) * | 1986-02-18 | 1987-07-28 | Reed Tool Company | Mounting means for cutting elements in drag type rotary drill bit |
US4743400A (en) * | 1986-09-22 | 1988-05-10 | Mcneilab, Inc. | Process for preparing retinoyl chlorides |
AU6141490A (en) | 1989-07-28 | 1991-03-11 | Sloan-Kettering Institute For Cancer Research | Growth factors containing vitamin a or other retinoids and uses thereof |
US5814612A (en) * | 1991-04-09 | 1998-09-29 | Sloan-Kettering Institute For Cancer Research | Retinol derivatives and uses thereof |
US6506917B1 (en) * | 1991-12-18 | 2003-01-14 | The Salk Institute For Biological Studies | Compounds and compositions useful for modulation of processes mediated by RXR |
US6050354A (en) * | 1992-01-31 | 2000-04-18 | Baker Hughes Incorporated | Rolling cutter bit with shear cutting gage |
US5314909A (en) * | 1993-03-17 | 1994-05-24 | Merck & Co., Inc. | Use of non-steroidal antiiflammatory agents in macular degeneration |
US5399757A (en) * | 1993-07-20 | 1995-03-21 | Ortho Pharmaceutical Corporation | Process for the preparation of N-(4-hydroxyphenyl)-retinamide |
US5824685A (en) * | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
US5596011A (en) | 1995-04-06 | 1997-01-21 | Repine; Karen M. | Method for the treatment of macular degeneration |
US5702357A (en) * | 1995-06-07 | 1997-12-30 | Cobe Laboratories, Inc. | Extracorporeal blood processing methods and apparatus |
US5706906A (en) * | 1996-02-15 | 1998-01-13 | Baker Hughes Incorporated | Superabrasive cutting element with enhanced durability and increased wear life, and apparatus so equipped |
US5758733A (en) * | 1996-04-17 | 1998-06-02 | Baker Hughes Incorporated | Earth-boring bit with super-hard cutting elements |
US5846220A (en) * | 1996-04-30 | 1998-12-08 | Medtronic, Inc. | Therapeutic method for treatment of Alzheimer's disease |
US6034211A (en) * | 1996-06-03 | 2000-03-07 | Kelly; Jeffery W. | β-sheet nucleating peptidomimetics |
GB9621217D0 (en) * | 1996-10-11 | 1996-11-27 | Camco Drilling Group Ltd | Improvements in or relating to preform cutting elements for rotary drill bits |
AU5727798A (en) | 1996-12-23 | 1998-07-17 | Texas A & M University, The | Anti-amyloidogenic agents |
US5955305A (en) * | 1997-04-28 | 1999-09-21 | Incyte Pharmaceuticals, Inc. | Human retinoid binding protein |
US5776915A (en) * | 1997-08-12 | 1998-07-07 | Clarion Pharmaceuticals Inc. | Phosphocholines of retinoids |
CA2301032C (en) | 1997-08-15 | 2009-01-13 | Duke University | A method of preventing or treating estrogen-dependent diseases and disorders |
WO1999058126A1 (en) * | 1998-05-11 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
WO2001019770A2 (en) | 1999-09-14 | 2001-03-22 | Ligand Pharmaceuticals Incorporated | Rxr modulators with improved pharmacologic profile |
EP1232247A4 (en) | 1999-11-23 | 2003-06-18 | Gerhart Graupner | MODULATION OF SIGNAL TRANSDUCTION |
US20020031539A1 (en) * | 2000-08-30 | 2002-03-14 | The Brigham And Women's Hospital, Inc. | Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma |
EP1328262A2 (en) | 2000-10-17 | 2003-07-23 | Board of Regents, The University of Texas System | A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes |
US6408958B1 (en) * | 2000-10-23 | 2002-06-25 | Baker Hughes Incorporated | Superabrasive cutting assemblies including cutters of varying orientations and drill bits so equipped |
WO2002058689A1 (en) | 2000-12-05 | 2002-08-01 | Childrens Hospital Los Angeles | Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same |
US20030032078A1 (en) * | 2001-01-23 | 2003-02-13 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of macular and retinal degenerations |
CN1269799C (zh) | 2001-05-29 | 2006-08-16 | 株式会社开备传 | 新型类维生素a衍生物和所述化合物的生产方法以及包括所述化合物的抗癌药物组合物 |
ATE316088T1 (de) * | 2001-06-22 | 2006-02-15 | Merck & Co Inc | Tyrosin-kinase inhibitoren |
US6696606B2 (en) | 2001-07-06 | 2004-02-24 | The Ohio State University Research Foundation | Solid phase synthesis of arylretinamides |
US6599891B2 (en) * | 2001-07-20 | 2003-07-29 | Qlt Inc. | Treatment of macular edema |
US20030229062A1 (en) | 2001-12-07 | 2003-12-11 | The Regents Of The University Of California | Treatments for age-related macular degeneration (AMD) |
US20040014131A1 (en) | 2002-07-09 | 2004-01-22 | Pfizer Inc. | Assay methods |
WO2004041160A2 (en) * | 2002-10-30 | 2004-05-21 | University Of Kentucky Research Foundation | Methods and animal model for analyzing age-related macular degeneration |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
AU2003294757A1 (en) | 2002-11-29 | 2004-06-23 | Axxima Pharmaceuticals Ag | Formulations useful against hepatitis c virus infections |
SI21392A (sl) | 2002-12-24 | 2004-06-30 | Vinko Kunc | Postopek za avtomatsko nastavitev ojačenja izpraševalnikovega sprejemnika v brezkontaktnem identifikacijskem sistemu |
PT1594544T (pt) | 2003-01-31 | 2016-07-14 | Los Angeles Childrens Hospital | Composições orais de fenretinida tendo biodisponibilidade aumentada e métodos de utilização das mesmas |
FI20030426A (fi) | 2003-03-24 | 2004-09-25 | Tomi Jaervinen | Syklodekstriinikompleksit |
US7178609B2 (en) * | 2003-08-19 | 2007-02-20 | Baker Hughes Incorporated | Window mill and drill bit |
EP1692521A1 (en) | 2003-12-11 | 2006-08-23 | Beth Israel Deaconess Medical Center, Inc. | Rbp4 in insulin sensitivity/resistance, diabetes, and obesity |
WO2005077176A1 (en) | 2004-02-11 | 2005-08-25 | The Trustees Of Columbia University In The City Of New York | Anthocyanin compounds and methods of use thereof |
KR20060135819A (ko) * | 2004-02-17 | 2006-12-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 황반변성을 포함하는 안과질환의 관리 |
US7566808B2 (en) | 2004-02-17 | 2009-07-28 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
EP1727529B1 (en) | 2004-03-17 | 2016-03-02 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
BRPI0511396B1 (pt) | 2004-06-18 | 2021-07-27 | University Of Washington | Uso de 9-cis-retinil éster e uso de um derivado de retinal sintético |
EP1768657B1 (en) | 2004-06-23 | 2008-08-13 | Sirion Therapeutics, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivates |
US7286860B2 (en) | 2004-07-23 | 2007-10-23 | Dyna Llc | Systems and methods for a comfortable wireless communication device |
EP1778207A2 (en) | 2004-08-18 | 2007-05-02 | Sytera Inc. | Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
KR20070091283A (ko) | 2004-11-04 | 2007-09-10 | 시리온 테라퓨틱스, 인크. | 레티놀-레티놀 결합단백질(rbp)-트랜스타이레틴(ttr) 복합체 형성의조절 인자 |
EP2289500A1 (en) | 2004-12-08 | 2011-03-02 | ReVision Therapeutics, Inc. | Retinol binding protein and transthyretin modulators for treating hypertosis, Alzheimer's disease or idiopathic intracranial hypertension |
UA81382C2 (en) * | 2005-07-11 | 2007-12-25 | Composition for treating retinol-related diseases by modulation of retinol binding |
-
2005
- 2005-06-06 EP EP05758777A patent/EP1768657B1/en not_active Not-in-force
- 2005-06-06 KR KR1020077001270A patent/KR100862930B1/ko not_active IP Right Cessation
- 2005-06-06 AT AT05758777T patent/ATE404188T1/de active
- 2005-06-06 WO PCT/US2005/020080 patent/WO2006007314A1/en active Application Filing
- 2005-06-06 EP EP08014275A patent/EP2025336A1/en not_active Withdrawn
- 2005-06-06 DE DE602005008970T patent/DE602005008970D1/de active Active
- 2005-06-06 ES ES05758777T patent/ES2313368T3/es active Active
- 2005-06-06 BR BRPI0512569-3A patent/BRPI0512569A/pt not_active IP Right Cessation
- 2005-06-06 EA EA200700109A patent/EA011864B1/ru not_active IP Right Cessation
- 2005-06-06 EP EP10181656A patent/EP2277516A1/en not_active Withdrawn
- 2005-06-06 NZ NZ551955A patent/NZ551955A/en not_active IP Right Cessation
- 2005-06-06 PL PL05758777T patent/PL1768657T3/pl unknown
- 2005-06-06 SG SG200801546-3A patent/SG140607A1/en unknown
- 2005-06-06 GE GEAP20059816A patent/GEP20084520B/en unknown
- 2005-06-06 CA CA2569691A patent/CA2569691C/en not_active Expired - Fee Related
- 2005-06-06 DK DK05758777T patent/DK1768657T3/da active
- 2005-06-06 JP JP2007518098A patent/JP4855396B2/ja not_active Expired - Fee Related
- 2005-06-06 AU AU2005262558A patent/AU2005262558B8/en not_active Ceased
- 2005-06-06 SI SI200530415T patent/SI1768657T1/sl unknown
- 2005-06-06 MX MXPA06014978A patent/MXPA06014978A/es active IP Right Grant
- 2005-06-06 PT PT05758777T patent/PT1768657E/pt unknown
- 2005-06-10 US US11/150,641 patent/US8314152B2/en not_active Expired - Fee Related
- 2005-06-21 AR ARP050102545A patent/AR049929A1/es not_active Application Discontinuation
- 2005-06-22 TW TW094120880A patent/TWI396532B/zh not_active IP Right Cessation
-
2006
- 2006-12-06 IL IL179872A patent/IL179872A/en not_active IP Right Cessation
-
2007
- 2007-01-19 LV LVP-07-05A patent/LV13564B/lv unknown
- 2007-01-22 NO NO20070408A patent/NO20070408L/no not_active Application Discontinuation
- 2007-12-06 HK HK07113340.3A patent/HK1107671A1/xx not_active IP Right Cessation
-
2008
- 2008-11-12 CY CY20081101287T patent/CY1110435T1/el unknown
-
2010
- 2010-04-21 US US12/764,764 patent/US8410168B2/en not_active Expired - Fee Related
-
2011
- 2011-05-27 US US13/118,330 patent/US20110294891A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0512569A (pt) | métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano | |
WO2007150046A3 (en) | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity | |
MX2008000064A (es) | Metodos y composiciones para el tratamiento de condiciones oftalmicas via retinol de suero, proteina de enlace de retinol de suero (rbp) y/o modulacion de retinol-rbp del suero. | |
WO2006033734A3 (en) | Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders | |
PE20080053A1 (es) | Composiciones oftalmicas de alcaftadina | |
GEP20094644B (en) | Retinyl derivatives, compositions thereof and assays for treating retinol-related diseases | |
BR0317774A (pt) | Uso de rimexolona no tratamento de olho seco | |
NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
BR0317033A (pt) | Vitreólise farmacológica | |
NO20082044L (no) | Kombinasjonsterapi innbefattende substituerte oksazolidinoner for prevensjon og behandling av cerebrale kretslopssykdommer | |
MXPA06014470A (es) | Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas. | |
MY157944A (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associat ed with angiogenesis | |
BRPI0600199A (pt) | usos de ácido pinolênico ou um seu derivado e de uma composição | |
BRPI0607660A2 (pt) | recipientes de lìquido programáveis | |
PE20110023A1 (es) | Composiciones inmunogenicas de antigenos de staphylococcus aureus | |
IL181434A0 (en) | Neuroprotective effect of solubilized udca in focal ischemic model | |
MXPA05008570A (es) | Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion. | |
MX2009006685A (es) | Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos. | |
TW200727903A (en) | Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate | |
BR0109672A (pt) | Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente | |
HK1110207A1 (en) | Ophthalmic compositions and methods of using the same | |
MXPA04000839A (es) | Metodos y composiciones para el tratamiento de enfermedades oftalmicas. | |
FR2883182B1 (fr) | Composition de vitamines utiles dans le traitement des maladies oculaires | |
BRPI0417175A (pt) | composições, método para produzir essas composições, solução que as compreende e métodos para utilizar as mesmas | |
AU2016204146A1 (en) | Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: REVISION THERAPEUTICS, INC (US) Free format text: TRANSFERIDO DE: SIRION THERAPEUTICS, INC. |
|
B25G | Requested change of headquarter approved |
Owner name: REVISION THERAPEUTICS, INC (US) Free format text: SEDE ALTERADA CONFORME PET NO 020100070609 - RJ DE 30/07/2010. |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: SIRION THERAPEUTICS, INC. (US) Free format text: ANULADA A TRANSFERENCIA PUBLICADA NA RPI 2103 DE 26/04/2011, POR TER SIDO INDEVIDA |
|
B25A | Requested transfer of rights approved |
Owner name: REVISION THERAPEUTICS, INC. (US) Free format text: TRANSFERIDO DE: SIRION THERAPEUTICS, INC. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2310 DE 14-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B25H | Request for change of headquarter rejected |
Owner name: REVISION THERAPEUTICS, INC. (US) |